Therapeutic Effects of Silymarin in Patients With B-thalassemia Major

Status Active, not recruiting

Clinical Trial Summary

Silymarin, a flavonolignan complex isolated from Silybum marianum, has a strong antioxidant, hepatoprotective and iron chelating activities. The present study has been designed to investigate the therapeutic activity of orally administered silymarin in patients with thalassemia major under conventional iron chelation therapy. A 6-month randomized, double-blind, clinical trial was conducted in 140 beta-thalassemia major patients in two well-matched groups. Patients are randomized to receive a silymarin tablet (140 mg) three times a day plus conventional desferrioxamine therapy or the same therapy but a placebo tablet instead of silymarin. Clinical laboratory tests of iron status and liver function are assessed at the beginning and the end of the trial.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00999349
Study type	Interventional
Source	Isfahan University of Medical Sciences
Contact
Status	Active, not recruiting
Phase	Phase 2/Phase 3
Start date	March 2009

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04423237` - Risk Factors and Measures to Prevent Liver and Pancreas Complications in Pediatric Patients After HSCT
Completed	`NCT04614779` - Long-term Clinical Study of CN128 in Thalassemia Patients	Phase 2
Withdrawn	`NCT03800446` - Validation of a Point-of-care Device Measuring Ferritin With Capillary Blood	N/A
Not yet recruiting	`NCT02833493` - Study of MRI Monitoring in Patients With Aplastic Anemia and Low or Int-1 Risk of MDS Complicated With Iron Overload	N/A
Completed	`NCT02164253` - Focal Accumulation of Iron in Cerebral Regions in Early ALS (Amyotrophic Lateral Sclerosis) Patients	Phase 2
Completed	`NCT00512226` - Iron Overload Assesment in Sickle Cell Anemia and Sickle Cell Thalassemia	N/A
Completed	`NCT00901199` - Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron Overload	Phase 2
Recruiting	`NCT00378469` - Study of the Effects of Muscular Activity on Iron Metabolism	N/A
Completed	`NCT00117507` - Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients	Phase 4
Completed	`NCT00138684` - Cytochrome P450 2E1 and Iron Overload	Phase 2
Completed	`NCT03990181` - Inhibiting Dietary Iron Absorption in Subjects With Hereditary Hemochromatosis by a Natural Polyphenol Supplement	N/A
Terminated	`NCT02274233` - Safety and Pharmacokinetic Study of Escalating Doses of SP-420, an Iron Chelator, in Patients With β-Thalassemia	Phase 1
Active, not recruiting	`NCT01443195` - Iron Metabolism in Small Pre Term Newborns	N/A
Completed	`NCT01546415` - Safety and Efficacy of Desferasirox in Chinese Patients With Iron Overload and Aplastic Anemia	Phase 4
Completed	`NCT01572818` - Effects of Phlebotomy on Insulin Sensitivity in Insulin Resistance-associated Hepatic Iron Overload Patients	N/A
Not yet recruiting	`NCT00980421` - Safety of Various Mode of Delivery of Iron Supplement on Iron Toxicity Markers in Preschool Children	Phase 3
Completed	`NCT01047098` - Effects of Taking Prenatal Vitamin-mineral Supplements During Lactation on Iron Status and Markers of Oxidation	N/A
Recruiting	`NCT05294471` - Fully Automated High-Throughput Quantitative MRI of the Liver
Completed	`NCT03591575` - Safety and Efficacy of Early Treatment With Deferiprone in Infants and Young Children	Phase 4
Active, not recruiting	`NCT00907283` - Ferrochelating Treatment in Patients Affected by Neurodegeneration With Brain Iron Accumulation (NBIA)	Phase 2